XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Overview
NASDAQ:XERS - US98422E1038 - Common Stock
XERS Key Statistics, Chart & Performance
The current stock price of XERS is 7.83 USD. In the past month the price increased by 45.54%. In the past year, price increased by 178.65%.
XERS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.36 | 693.36B | ||
| JNJ | JOHNSON & JOHNSON | 17.72 | 426.69B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.48 | 250.88B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18 | 247.73B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.3 | 244.98B | ||
| MRK | MERCK & CO. INC. | 10.92 | 210.11B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 11.17 | 120.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.01 | 96.03B | ||
| GSK | GSK PLC-SPON ADR | 8.8 | 79.92B | ||
| ZTS | ZOETIS INC | 25.14 | 69.31B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.69 | 47.34B |
Related stock screener links
About XERS
Company Profile
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 394 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Company Info
XERIS BIOPHARMA HOLDINGS INC
1375 West Fulton Street, Suite 1300
Chicago ILLINOIS 60601 US
CEO: Paul R. Edick
Employees: 394
Phone: 18444455704
XERIS BIOPHARMA HOLDINGS INC / XERS FAQ
What is the stock price of XERIS BIOPHARMA HOLDINGS INC today?
The current stock price of XERS is 7.83 USD. The price decreased by -0.89% in the last trading session.
What is the ticker symbol for XERIS BIOPHARMA HOLDINGS INC stock?
The exchange symbol of XERIS BIOPHARMA HOLDINGS INC is XERS and it is listed on the Nasdaq exchange.
On which exchange is XERS stock listed?
XERS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for XERIS BIOPHARMA HOLDINGS INC stock?
12 analysts have analysed XERS and the average price target is 9.18 USD. This implies a price increase of 17.24% is expected in the next year compared to the current price of 7.83. Check the XERIS BIOPHARMA HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is XERIS BIOPHARMA HOLDINGS INC worth?
XERIS BIOPHARMA HOLDINGS INC (XERS) has a market capitalization of 1.26B USD. This makes XERS a Small Cap stock.
How many employees does XERIS BIOPHARMA HOLDINGS INC have?
XERIS BIOPHARMA HOLDINGS INC (XERS) currently has 394 employees.
What are the support and resistance levels for XERIS BIOPHARMA HOLDINGS INC (XERS) stock?
XERIS BIOPHARMA HOLDINGS INC (XERS) has a support level at 7.82. Check the full technical report for a detailed analysis of XERS support and resistance levels.
Is XERIS BIOPHARMA HOLDINGS INC (XERS) expected to grow?
The Revenue of XERIS BIOPHARMA HOLDINGS INC (XERS) is expected to grow by 42.48% in the next year. Check the estimates tab for more information on the XERS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy XERIS BIOPHARMA HOLDINGS INC (XERS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XERS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XERS, evaluating the profitability, health, valuation and growth aspects
- XERIS BIOPHARMA HOLDINGS INC (XERS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- XERIS BIOPHARMA HOLDINGS INC (XERS) Sales and EPS estimates to see what analysts future expectations are.
- XERIS BIOPHARMA HOLDINGS INC (XERS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- XERIS BIOPHARMA HOLDINGS INC (XERS) Insider and Institutional Ownership to learn about the owners and their transactions.
- XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Chart to make your own analysis
- XERIS BIOPHARMA HOLDINGS INC (XERS) Latest news and press-releases to stay up to date.
Does XERIS BIOPHARMA HOLDINGS INC (XERS) stock pay dividends?
XERS does not pay a dividend.
When does XERIS BIOPHARMA HOLDINGS INC (XERS) report earnings?
XERIS BIOPHARMA HOLDINGS INC (XERS) will report earnings on 2025-11-06, before the market open.
What is the Price/Earnings (PE) ratio of XERIS BIOPHARMA HOLDINGS INC (XERS)?
XERIS BIOPHARMA HOLDINGS INC (XERS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.21).
What is the Short Interest ratio of XERIS BIOPHARMA HOLDINGS INC (XERS) stock?
The outstanding short interest for XERIS BIOPHARMA HOLDINGS INC (XERS) is 11.88% of its float. Check the ownership tab for more information on the XERS short interest.
XERS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to XERS. When comparing the yearly performance of all stocks, XERS is one of the better performing stocks in the market, outperforming 97.25% of all stocks.
XERS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XERS. XERS has a bad profitability rating. Also its financial health evaluation is rather negative.
XERS Financial Highlights
Over the last trailing twelve months XERS reported a non-GAAP Earnings per Share(EPS) of -0.21. The EPS increased by 51.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.56% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
XERS Forecast & Estimates
12 analysts have analysed XERS and the average price target is 9.18 USD. This implies a price increase of 17.24% is expected in the next year compared to the current price of 7.83.
For the next year, analysts expect an EPS growth of 82.1% and a revenue growth 42.48% for XERS